Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: Patient choices and outcome

Familial Cancer

Volumn 11, Issue 3, 2012, Pages 473-482

  This, Pascale ^a   De La Rochefordière, Anne ^a   Savignoni, Alexia ^a   Falcou, Marie Christine ^a   Tardivon, Anne ^a   Thibault, Fabienne ^a   Alran, Séverine ^a   Fourchotte, Virgine ^a   Fitoussi, Alfred ^a   Couturaud, Benoit ^a   Dolbeault, Sylvie ^a   Salmon, Remy J ^a   Sigal Zafrani, Brigitte ^a   Asselain, Bernard ^a   Stoppa Lyonnet, Dominique ^a,b  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

BRCA1 2; Breast cancer; Ovarian cancer; Prophylactic mastectomy; Prophylactic salpingo oophorectomy

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; FEMALE; FRANCE; GENE MUTATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; OVARY CANCER; PRIORITY JOURNAL; RISK MANAGEMENT; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; FRANCE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MASTECTOMY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PREGNANCY; SALPINGECTOMY;

EID: 84870448644     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-012-9539-1     Document Type: Article

References (45)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130
2. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329-1333
3. Belot A, Velten M, Grosclaude P, Bossard N, Launoy G, Remontet L et al. 2008 Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2005. St Maurice (Fra): Institut de Veille sanitaire, décembre 2008. Disponible sur www.invs.sante.fr
4. Eisinger F, Alby N, Bremond A, Dauplat J, Espie M, Janiaud P et al (1998) Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol 9:939-950
5. Eisinger F, Bressac B, Castaigne D, Cottu P, Lansac J, Lefranc J et al (2004) Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l'ovaire (mise à jour 2004). Bull Cancer 91:219-237
6. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Is Fentiman, Me Robson et al (2008) Proceedings of the international consensus conference on breast cancer risk, genetics, and risk management, April, 2007. Cancer 113:2627-2637
7. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75-89
8. Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M et al (2011) Prospective Study of Breast Cancer Incidence in Women With a BRCA1 or BRCA2 Mutation Under Surveillance With and Without Magnetic Resonance Imaging. J Clin Oncol 29: 1664-1669
9. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121: 225-231
10. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967-975
11. Frost MH, Schaid DJ, Sellers TA, Slezak JM, Arnold PG, Woods JE et al (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319-324
12. Brandberg Y, Sandelin K, Erikson S, Jurell G, Liljegren A, Lindblom A et al (2008) Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year followup study. J Clin Oncol 26:3943-3949
13. Gahm J, Wickman M, Brandberg Y (2010) Bilateral prophylactic mastectomy in women with inherited risk of breast cancer-prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. Breast 19:462-469
14. Cuzick J (2005) Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23:1636-1643
15. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J et al (2011) Exemestane for breastcancer prevention in postmenopausal women. N Engl J Med 364:2381-2391
16. Pujol P, Lasset C, Berthet P, Dugast C, Delaloge S, Fricker JP et al (2012) Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. Fam Cancer 11:77-84
17. Woodward ER, Sleightholme HV, Considine AM, Williamson S, Mchugo JM, Cruger DG (2007) Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 114:1500-1509
18. Inca (2009) Principales recommandations de prise en charge des personnes porteuses d'une mutation de BRCA 1 ou BRCA2 In: http://wwwe-cancerfr/soins/ prise-en-charge-specifiques/oncoge'ne'tique
19. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80-87
20. Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pages S, Ithier G, Ligot L et al (1997) BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 60:1021-1030
21. Gad S, Caux-Moncoutier V, Pages-Berhouet S, Gauthier-Villars M, Coupier I, Pujol P et al (2002) Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families. Oncogene 21:6841-6847
22. Tournier I, Bb Paillerets, Sobol H, Stoppa-Lyonnet D, Lidereau R, Barrois M et al (2004) Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 64:8143-8147
23. Weber J, Miserere S, Champ J, Looten R, Stoppa-Lyonnet D, Viovy JL et al (2007) High-throughput simultaneous detection of point mutations and large-scale rearrangements by CE. Electrophoresis 28:4282-4288
24. Caux-Moncoutier V, Castera L, Tirapo C, Michaux D, Remon MA, Lauge A et al (2010) EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients. Hum Mutat 32:325-334
25. R Development Core Team (2010) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/
26. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI et al (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-3636
27. Wainberg S, Husted J (2004) Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 13: 1989-1995
28. Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, BaildamAD et al (2009) Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev 18:2318-2324
29. Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J et al (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268
30. Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Seynaeve C et al (2002) One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 73:97-112
31. Julian-Reynier CM, Bouchard LJ, Evans DG, Eisinger FA, Foulkes WD, Kerr B et al (2001) Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92:959-968
32. Julian-Reynier C, Eisinger F, Evans G, Foulkes W, Sobol H (2000) Variation in prophylactic surgery decisions. Lancet 356:1687
33. Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA et al (2008) Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 10:161-166
34. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804-7810
35. This P, Salmon RJ, Dolbeault S, De La Rochefordiere A, Sigal-Zafrani B, Stoppa-Lyonnet D (2005) Hormone replacement therapy after prophylactic adnexectomy. Hered Cancer Clin Pract 3:181-182
36. Meijers-Heijboer H, Van Geel B, Van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164
37. Milne RL, Antoniou AC (2011) Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann Oncol 22(Suppl 1):i11-i17
38. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296:185-192
39. Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X et al (2007) Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 109:1784-1790
40. Robson M, Offit K (2007) Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 357: 154-162
41. Kurian AW, Sigal BM, Plevritis SK (2010) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28:222-231
42. Grann VR, Patel PR, Jacobson JS, Warner E, Df Heitjan, Ashby-Thompson M et al (2011) Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat 125:837-847
43. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL (2010) The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 7:708-717
44. Metcalfe KA, Poll A, O'connor A, Gershman S, Armel S, Finch A et al (2007) Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Clin Genet 72:208-217
45. Landsbergen KM, Prins JB, Kamm YJ, Brunner HG, Hoogerbrugge N (2010) Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years. Fam Cancer 9:213-220